Matches in SemOpenAlex for { <https://semopenalex.org/work/W3193629591> ?p ?o ?g. }
- W3193629591 endingPage "1025" @default.
- W3193629591 startingPage "1013" @default.
- W3193629591 abstract "There are increasing data on the association between non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD).To summarise evidence on the association between NAFLD and CVD in the clinical setting and provide potential therapeutic implications.We searched PubMed. Evidence was primarily derived from meta-analyses. and then, if data were insufficient, from clinical trials, and then from observational studies.NAFLD has been linked to arterial hypertension, arterial stiffness, atherosclerosis, coronary artery disease, atrial fibrillation and aortic valvular sclerosis. Advanced liver fibrosis is a crucial prognostic factor for end-stage liver disease and for cardiovascular and overall mortality. Weight loss through lifestyle modifications (diet and exercise) remains the cornerstone of the management of both NAFLD and CVD, but is difficult to achieve and possibly more difficult to sustain long term. Therefore, pharmacological management of NAFLD seems to be important, although no licenced medication currently exists. Pioglitazone, proposed for non-alcoholic steatohepatitis (NASH) by most guidelines, increases weight and should be avoided in congestive heart failure. Statins should not be avoided in NAFLD patients at risk for CVD. Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter-2 inhibitors, two classes of anti-diabetic drugs, have shown promising results in NAFLD and CVD, but more studies with hard end points are needed. Obeticholic acid, a promising medication for NASH under investigation, should be carefully considered, owing to its adverse effect on lipid profile.NAFLD is associated with CVD, which may have certain clinical and therapeutic implications." @default.
- W3193629591 created "2021-08-30" @default.
- W3193629591 creator A5002779497 @default.
- W3193629591 creator A5009873146 @default.
- W3193629591 creator A5045916850 @default.
- W3193629591 date "2021-08-20" @default.
- W3193629591 modified "2023-10-11" @default.
- W3193629591 title "Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations" @default.
- W3193629591 cites W1490555655 @default.
- W3193629591 cites W1540165847 @default.
- W3193629591 cites W1622799587 @default.
- W3193629591 cites W1810034819 @default.
- W3193629591 cites W1848828990 @default.
- W3193629591 cites W1922087192 @default.
- W3193629591 cites W1983586642 @default.
- W3193629591 cites W1983933673 @default.
- W3193629591 cites W2047189101 @default.
- W3193629591 cites W2062812115 @default.
- W3193629591 cites W2063437798 @default.
- W3193629591 cites W2080927191 @default.
- W3193629591 cites W2106768039 @default.
- W3193629591 cites W2120822075 @default.
- W3193629591 cites W2128460332 @default.
- W3193629591 cites W2140068099 @default.
- W3193629591 cites W2163076395 @default.
- W3193629591 cites W2168342632 @default.
- W3193629591 cites W2204688218 @default.
- W3193629591 cites W2210672989 @default.
- W3193629591 cites W2211370063 @default.
- W3193629591 cites W2215535790 @default.
- W3193629591 cites W2222290303 @default.
- W3193629591 cites W2236539608 @default.
- W3193629591 cites W2256856541 @default.
- W3193629591 cites W2275424014 @default.
- W3193629591 cites W2297168848 @default.
- W3193629591 cites W2345184150 @default.
- W3193629591 cites W2346495725 @default.
- W3193629591 cites W2399261310 @default.
- W3193629591 cites W2408388024 @default.
- W3193629591 cites W2482987121 @default.
- W3193629591 cites W2519289952 @default.
- W3193629591 cites W2520428730 @default.
- W3193629591 cites W2520937493 @default.
- W3193629591 cites W2550194700 @default.
- W3193629591 cites W2556325138 @default.
- W3193629591 cites W2561330046 @default.
- W3193629591 cites W2565809852 @default.
- W3193629591 cites W2568210207 @default.
- W3193629591 cites W2580009538 @default.
- W3193629591 cites W2591950918 @default.
- W3193629591 cites W2593506275 @default.
- W3193629591 cites W2605795744 @default.
- W3193629591 cites W2611881317 @default.
- W3193629591 cites W2619682975 @default.
- W3193629591 cites W2732221304 @default.
- W3193629591 cites W2734724639 @default.
- W3193629591 cites W2734959400 @default.
- W3193629591 cites W2751199194 @default.
- W3193629591 cites W2754453313 @default.
- W3193629591 cites W2765613816 @default.
- W3193629591 cites W2769607536 @default.
- W3193629591 cites W2771229928 @default.
- W3193629591 cites W2795296652 @default.
- W3193629591 cites W2800181731 @default.
- W3193629591 cites W2800368679 @default.
- W3193629591 cites W2801542002 @default.
- W3193629591 cites W2890862149 @default.
- W3193629591 cites W2892751109 @default.
- W3193629591 cites W2896985838 @default.
- W3193629591 cites W2902419609 @default.
- W3193629591 cites W2909892282 @default.
- W3193629591 cites W2916103033 @default.
- W3193629591 cites W2921012991 @default.
- W3193629591 cites W2955615964 @default.
- W3193629591 cites W2969124264 @default.
- W3193629591 cites W2969816356 @default.
- W3193629591 cites W2971733664 @default.
- W3193629591 cites W2993083975 @default.
- W3193629591 cites W3000690474 @default.
- W3193629591 cites W3004644667 @default.
- W3193629591 cites W3005906362 @default.
- W3193629591 cites W3008837192 @default.
- W3193629591 cites W3009902673 @default.
- W3193629591 cites W3012544245 @default.
- W3193629591 cites W3015579983 @default.
- W3193629591 cites W3017352380 @default.
- W3193629591 cites W3018009095 @default.
- W3193629591 cites W3024628764 @default.
- W3193629591 cites W3026878893 @default.
- W3193629591 cites W3036171623 @default.
- W3193629591 cites W3089992197 @default.
- W3193629591 cites W3092021678 @default.
- W3193629591 cites W3094082710 @default.
- W3193629591 cites W3102426258 @default.
- W3193629591 cites W3111342436 @default.
- W3193629591 cites W3111918002 @default.
- W3193629591 cites W3112103684 @default.
- W3193629591 cites W3120821309 @default.